- Lexaria
Bioscience is dedicated to providing healthful alternatives to
drug-substance inhalation by providing an edible technology that works as
effectively as smoking or vaping at getting substances into the
bloodstream
- The
company’s DehydraTECH platform has been licensed to multiple companies in
the cannabis and tobacco industries, and Canada’s recent nationwide
legalization of cannabis edibles is expected to open even more of a market
- Gregg
Smith, the founder of a New York-based “culture tech” venture investment
firm, has joined Lexaria as a senior advisor to help define the company’s
leadership strategies
Innovations in drug delivery are making the wellness product
market safer and more effective in its niche as an alternative to costly
pharmaceuticals or foreign remedies that lack governmental approval.
Bio-delivery technology developer Lexaria
Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) is a world leader in edible
drug science to combat the ills of substances that might otherwise be inhaled
into the lungs.
Lexaria’s proprietary DehydraTECH™ drug delivery platform is
patented to work with existing substances such as nicotine, cannabidiol (CBD)
and other non-psychoactive and psychoactive cannabinoids to get orally
ingestible versions of the substances into the bloodstream at speeds comparable
to inhaled products, virtually eliminating a key reason people might risk
sustained injury to their lungs to use those products.
“Wherever there are many victims from past injustices, there
is a lot of anger and resentment that doesn’t go away easily,” CEO Chris Bunka
told Forbes in discussing Lexaria’s aim to get nicotine users to move away from
“life-threatening” smoking habits to satisfy their cravings (http://ibn.fm/oMc9G). “My father
also died from lung cancer just last year, so I am no fan. … The fact that
(DehydraTECH) is fast means that smokers might not be frustrated waiting for
their nicotine experience to begin, the way they have been with traditional
nicotine products such as gums and lozenges.”
Lexaria recently announced the appointment of Gregg Smith,
the founder of a New York-based “culture tech” venture investment firm, as a
senior advisor in helping define Lexaria’s leadership strategies.
“I am passionate about creating a smokeless future and
recognize that the consumption methods of nicotine and cannabis will change,”
Smith stated in the news release (http://ibn.fm/Srpvg). “Lexaria’s technology, DehydraTECH™,
will completely disrupt and improve the consumption and delivery of oral
nicotine, CBD and cannabis. Lexaria’s recognition of the recent FDA recognition
of certain oral delivery forms of nicotine as ‘less harmful’ to human health
than combustible smoking will be a driving force of changing consumer
preferences.”
One strategy Lexaria has already been pursuing includes
introducing DehydraTECH-licensed products to consumers through adult-format
beverages, building on a relationship with Toronto-based Hill Street Beverage
Company Inc. (TSX.V: BEER), a company renowned for its alcohol-free beers and
wines.
“Our alcohol-free business continues to grow as more and
more people turn away from alcohol and look for better alternatives. But we’re
more than just the world’s most award-winning alcohol-free beverage company,”
Hill Street’s website states (http://ibn.fm/JvQRy).
“We’ve licensed a technology that allows us to take that award-winning
adult-beverage portfolio and infuse it with cannabis… without any impact to the
smell or the taste of the product.”
Canada legalized cannabis-infused edibles and beverages in
October, and the first products are expected to begin hitting store shelves
soon (http://ibn.fm/80XHA).
Market analysts at Deloitte predict the Canadian market for
edibles and alternative cannabis products alone will be worth $2.7 billion a
year, and that cannabis extract-based products including edibles will make up
nearly 60 percent of the total at $1.6 billion (http://ibn.fm/1VkfJ).
Lexaria has already licensed its technology to multiple
companies in North America in the cannabis and tobacco industries. The company
operates a licensed in-house research laboratory and its IP portfolio includes
16 patents granted and over 60 patents pending worldwide.
For more information, visit the company’s website at www.LexariaBioscience.com
NOTE TO INVESTORS: The latest news and updates
relating to LXRP are available in the company’s newsroom at http://ibn.fm/LXRP
About MissionIR
MissionIR is
primarily focused on strategic communications. We have executed countless
communications programs to address the needs of companies ranging from
start-ups to established industry leaders, gaining valuable experience and the
expertise necessary to determine the most effective strategy for any given
situation.
For more information, visit www.MissionIR.com
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
